Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

About

Advertise

Privacy

Editorial

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times - Ophthalmology news, articles, and events

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

View

Advanced Therapies for Retinal Vascular Diseases: Enhancing Durability and Reducing Treatment Burden

Video Series

Safety of Advanced Therapies in Clinical Trials vs Real World Experience 

Videos

A panel of retina specialists discuss highlights from a recent 

event discussing advanced therapies for retinal vascular diseases through patient cases of diabetic macular edema, central retinal vein occlusion, and more.

In the first case, David Lally, MD presents a patient case of age-related macular degeneration (AMD) highlighting the superior durability of newer treatments.

Case 1: Treatment-Naïve Neovascular Age-Related Macular Degeneration

Sumit Sharma, MD, FASRS asks the panel what they are using for first-line AMD treatment and what considerations factor into decision making, such as insurance coverage or risk of inflammation. 

First Line Treatment Decisions for Age-Related Macular Degeneration

In the second case, Scott D. Walter, MD, MSc, FASRS presents a patient case of diabetic macular edema (DME) where each eye was treated with a different agent. Walter presents optical coherence tomograph (OTC) outcome similarities and differences in key criteria, such as neovascularization, micro aneurism leakage, and macular leakage. 

Case 2: Diabetic Macular Edema With Severe Vision Loss

Sumit Sharma, MD, FASRS ponders to the panel the root cause of improved outcomes with newer agents. The panel then highlights current gaps in measuring visual improvements beyond tools such as the OCT, emphasizing the need for patient-centered treatment plans.

MOA and Improved Outcomes: Gaps in Measuring Real-World Results

In the third case, moderator Lisa J. Faia, MD presents her case of persistently active central retinal vein occlusion (CRVO), explaining her approach to switching this treatment-resistant patient to a newer agent. 

Case 3: Persistently Active Central Retinal Vein Occlusion

Lisa J. Faia, MD asks the panel about their concerns regarding the safety of newer agents for the broad array of retinal vascular diseases, highlighting the similarities and differences between clinical trial outcomes and real-world results. 

I'm sorry, but it seems there is no article text provided for me to summarize and extract key takeaways from. Could you please provide the text of the article

Safety of Advanced Therapies in Clinical Trials vs Real World Experience

EP: 1.Case 1: Treatment-Naïve Neovascular Age-Related Macular Degeneration

EP: 2.First Line Treatment Decisions for Age-Related Macular Degeneration

EP: 3.Case 2: Diabetic Macular Edema With Severe Vision Loss

EP: 4.MOA and Improved Outcomes: Gaps in Measuring Real-World Results

EP: 5.Case 3: Persistently Active Central Retinal Vein Occlusion

EP: 6.Safety of Advanced Therapies in Clinical Trials vs Real World Experience